Carlsmed, Inc. Selling and Marketing Expense
Carlsmed, Inc. (CARL) reported Selling and Marketing Expense of $11.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-05
- Carlsmed, Inc. selling and marketing expense for the quarter ending 2026-06-30 was $11.92M, a 51.48% increase year-over-year.
- Carlsmed, Inc. selling and marketing expense for the quarter ending 2026-03-31 was $10.30M, a 52.80% increase year-over-year.
- Carlsmed, Inc. selling and marketing expense for the quarter ending 2025-12-31 was $10.81M, a 69.42% increase year-over-year.
- Carlsmed, Inc. selling and marketing expense for the quarter ending 2025-09-30 was $9.61M, a 45.12% increase year-over-year.
- Carlsmed, Inc. selling and marketing expense for fiscal 2025 was $35.03M, a 63.13% increase from fiscal 2024.
- Carlsmed, Inc. selling and marketing expense for fiscal 2024 was $21.47M.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.92M 10-Q · filed 2026-08-05 | $22.22M 10-Q · filed 2026-08-05 | $33.03M derived: sum of 3 quarters · filed 2026-08-05 | $42.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $10.30M 10-Q · filed 2026-05-05 | $21.11M derived: sum of 2 quarters · filed 2026-05-05 | $30.72M derived: sum of 3 quarters · filed 2026-05-05 | $38.59M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $10.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $20.42M derived: sum of 2 quarters · filed 2026-02-25 | $28.29M derived: sum of 3 quarters · filed 2026-08-05 | $35.03M 10-K · filed 2026-02-25 |
| 2025-09-30 | $9.61M 10-Q · filed 2025-11-06 | $17.48M derived: sum of 2 quarters · filed 2026-08-05 | $24.22M 10-Q · filed 2025-11-06 | $30.60M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $7.87M 10-Q · filed 2026-08-05 | $14.61M 10-Q · filed 2026-08-05 | $20.99M derived: sum of 3 quarters · filed 2026-08-05 | $27.61M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $6.74M 10-Q · filed 2026-05-05 | $13.12M derived: sum of 2 quarters · filed 2026-05-05 | $19.74M derived: sum of 3 quarters · filed 2026-05-05 | $24.61M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $6.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $13.00M derived: sum of 2 quarters · filed 2026-02-25 | $17.88M derived: sum of 3 quarters · filed 2026-02-25 | $21.47M 10-K · filed 2026-02-25 |
| 2024-09-30 | $6.62M 10-Q · filed 2025-11-06 | $11.49M derived: sum of 2 quarters · filed 2025-11-06 | $15.09M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $4.87M 10-Q · filed 2025-08-28 | $8.47M 10-Q · filed 2025-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| NeuroPace Inc (NPCE) | United States | $0.480B | -28.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |